Drug intelligence / Profile preview

Ancaine

Development stage: Unknown
Lead developer: Sinocelltech
Modality: Recombinant Proteins and Enzymes
Administration: Intravenous

Overview

Ancaine (SCT800) is a recombinant human coagulation factor VIII (rFVIII) developed by Sinocelltech for the treatment and prophylaxis of bleeding in patients with hemophilia A. It is produced using recombinant DNA technology in Chinese Hamster Ovary (CHO) cells. As a replacement therapy, it restores the activity of factor VIII, which is deficient or absent in hemophilia A patients, thereby enabling the formation of a stable blood clot. Ancaine was the first domestically developed recombinant factor VIII to be approved in China, receiving marketing authorization from the NMPA in July 2021.

Brand names: Ancaine安佳满
Other names: recombinant human coagulation factor VIIIrFVIII

Targets

Coagulation Factor IXaPPL (Procoagulant phospholipid membrane)BB-031 (Von Willebrand factor)

Beyond the preview

Go deeper on Ancaine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ancaine.

Explore the full profile